The clinical success of modern anti-VEGF therapies is undeniable, yet the real-world management of chronic retinal conditions remains heavily burdened by the necessity of frequent, ongoing intravitreal injections. This intensive injection schedule often leads to significant patient fatigue, poor compliance rates, and a gradual, avoidable decline in long-term visual outcomes over extended...